Aug. 19 Clinical Quick Takes: Kalytera's cannabidiol shows promise for transplant, plus Abbisko and Brigham and Women's

Kalytera's CBD prevents graft-vs-host disease
Kalytera Therapeutics Inc. (TSX-V:KLY; OTCQB:KALTF) announced plans to start a Phase III registrational trial of cannabidiol after low and medium doses

Read the full 250 word article

User Sign In